🟢 Insulet Corporation is trading 4.5% up today on Omnipod 5 upgrade and Abbott sensor integration

Insulet Corporation is trading 4.5% up today at $152.93 after investors reacted positively to the U.S. rollout of enhancements for the Omnipod 5 insulin delivery system.

• The upgrade includes an improved algorithm with a lower 100 mg/dL glucose target and new compatibility with Abbott’s FreeStyle Libre 3 sensor.
• Shares are outperforming the broader market as the company begins the commercial launch of these technological updates.